Gonadal damage in Hodgkin's disease from cancer chemotherapeutic regimens

G. Bonadonna, A. Santoro, S. Viviani

Research output: Contribution to journalArticlepeer-review


The paper re-emphasizes that intesive prolonged anticancer chemotherapy containing alkylating agents or procarbazine or both produces a high-incidence of gonadal failure, particularly in males. This evidence has been documented mostly in patients with Hodgkin's disease. On the contrary, effective combination regimens, such as ABVD, not including the above mentioned drugs induce a comparatively less and transient germ cell toxicity. In devising chemotherapy for potentially curable neoplastic diseases in young patients efforts should be made to avoid or minimize the potential risk of drug-induced gonadal failure.

Original languageEnglish
Pages (from-to)140-145
Number of pages6
JournalArchives of Toxicology
Issue numberSUPPL. 7
Publication statusPublished - 1984

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis
  • Medicine(all)


Dive into the research topics of 'Gonadal damage in Hodgkin's disease from cancer chemotherapeutic regimens'. Together they form a unique fingerprint.

Cite this